Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.

34 In the randomized phase II KATE‐2 study, the combination of T‐DM1 and atezolizumab showed a trend for an OS benefit in trastuzumab‐pretreated HER2‐positive, PD‐L1 positive population, compared with T‐DM1 monotherapy. 35 As immunotherapy has shown activity and durable clinical benefit in patients with PD‐L1‐positive, trastuzumab‐resistant HER2‐positive breast cancer, further studies of the levels of TILs, the PD‐L1 status, and clinical benefits of immunotherapy on the HER2 mutations population are needed.

also in 53,322 other papers